ES2304452T3 - Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas. - Google Patents

Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas. Download PDF

Info

Publication number
ES2304452T3
ES2304452T3 ES02774525T ES02774525T ES2304452T3 ES 2304452 T3 ES2304452 T3 ES 2304452T3 ES 02774525 T ES02774525 T ES 02774525T ES 02774525 T ES02774525 T ES 02774525T ES 2304452 T3 ES2304452 T3 ES 2304452T3
Authority
ES
Spain
Prior art keywords
hdl
ischemia
treatment
reperfusion
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02774525T
Other languages
English (en)
Spanish (es)
Inventor
Alphonse Hubsch
Markus G. Lang
Peter G. Lerch
Roberto Paterno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by CSL Behring AG filed Critical CSL Behring AG
Application granted granted Critical
Publication of ES2304452T3 publication Critical patent/ES2304452T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
ES02774525T 2001-08-20 2002-08-20 Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas. Expired - Lifetime ES2304452T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
US313605P 2001-08-20
EP01120026 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (1)

Publication Number Publication Date
ES2304452T3 true ES2304452T3 (es) 2008-10-16

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02774525T Expired - Lifetime ES2304452T3 (es) 2001-08-20 2002-08-20 Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.

Country Status (10)

Country Link
US (2) US20040266660A1 (https=)
EP (1) EP1425031B8 (https=)
JP (1) JP4284177B2 (https=)
AT (1) ATE396736T1 (https=)
AU (1) AU2002340825B2 (https=)
CA (1) CA2457840C (https=)
DE (1) DE60226881D1 (https=)
ES (1) ES2304452T3 (https=)
WO (1) WO2003018047A2 (https=)
ZA (1) ZA200401360B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
CN102802618B (zh) 2009-06-25 2014-06-18 泰特拉有限公司 烟酸和米曲肼的治疗组合
JP2012532919A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療因子を含むｈｄｌおよび治療における使用
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2012103163A2 (en) * 2011-01-25 2012-08-02 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
US12599677B2 (en) 2020-10-05 2026-04-14 Northwestern University Targeted PH sensitive liposomes
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
JP4284177B2 (ja) 2009-06-24
ZA200401360B (en) 2005-08-31
WO2003018047A2 (en) 2003-03-06
EP1425031B8 (en) 2008-09-03
DE60226881D1 (de) 2008-07-10
HK1064304A1 (en) 2005-01-28
AU2002340825B2 (en) 2007-07-05
JP2005501110A (ja) 2005-01-13
CA2457840C (en) 2011-10-11
US20080108550A1 (en) 2008-05-08
CA2457840A1 (en) 2003-03-06
EP1425031B1 (en) 2008-05-28
US20040266660A1 (en) 2004-12-30
WO2003018047A3 (en) 2004-01-29
US7491693B2 (en) 2009-02-17
ATE396736T1 (de) 2008-06-15
EP1425031A2 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
ES2304452T3 (es) Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.
AU2002340825A1 (en) HDL for the treatment of stroke and other ischemic conditions
Yin et al. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic–ischemic brain injury via inhibition of caspases and AIF
ES2335437T3 (es) Composiciones farmaceuticas oftalmicas a base de aminoacidos y de hialuronato de sodio.
WO2013059791A2 (en) Methods and compositions for promoting axon regeneration and nerve function
EA010650B1 (ru) Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
CN107427549A (zh) 用于抑制血管生成的肽
KR101933543B1 (ko) 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
ES2229507T3 (es) Sales de peptidos bpc que tienen una actividad protectora del organismo, procedimiento para su obtencion y su utilizacion en terapia.
ES2389507T3 (es) Método para el tratamiento o la prevención de la insuficiencia multiorgánica
ES2263582T3 (es) Utilizacion del factor de crecimiento para prevenir o tratar cardiopatias isquemicas o accidentes cardiovasculares.
TWI311485B (en) Reconstituted hdl for the treatment of stroke and ischemic conditions
HK1064304B (en) Hdl for the treatment of stroke and other ischemic conditions
RU2826364C1 (ru) Способ лечения черепно-мозговой травмы и средство для его осуществления
US20100189802A1 (en) Method for treatment of vascular hyperpermeability
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
EP1285662A1 (en) Reconstituted HDL for the treatment of stroke and ischemic conditions
EP3233102A1 (en) Use of one or more antimicrobial peptides to induce cell death in various types of cancers
JP5870369B2 (ja) 血液脳関門障害改善剤
RU2766681C1 (ru) Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, для лечения синдрома ишемии-реперфузии у пациентов с ишемическими поражениями органов и конечностей
WO2025023864A1 (ru) Способ лечения черепно-мозговой травмы и средство для его осуществления
US20050256040A1 (en) Artificially designed pore-forming proteins with anti-tumor effects
Gao et al. The protective effect of a short peptide derived from cold-inducible RNA-binding protein in a rat model of cardiac arrest and resuscitation
CN117835998A (zh) 促凝血肽及其应用